An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. (Q50851780)
Jump to navigation
Jump to search
scientific article published on 5 July 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. |
scientific article published on 5 July 2013 |
Statements
An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. (English)
1 reference
1 reference
P Schöffski
1 reference
D Adkins
1 reference
T Gil
1 reference
A D Elias
1 reference
G K Pennock
1 reference
H Youssoufian
1 reference
H Gelderblom
1 reference
R Willey
1 reference
D O Grebennik
1 reference
5 July 2013
1 reference
49
1 reference
15
1 reference
3219-3228
1 reference